Platelets · 2020
A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roncati Luca, Ligabue Giulia, Nasillo Vincenzo, Lusenti Beatrice, Gennari William, Fabbiani Luca, Malagoli Claudia, Gallo Graziana, Giovanella Silvia, Lupi Massimo, Salviato Tiziana, Paolini Ambra, Costantini Matteo, Trenti Tommaso, Maiorana Antonio
Аннотация
Coronavirus disease 2019 (COVID-19) is a global public health emergency with many clinical facets, and new knowledge about its pathogenetic mechanisms is deemed necessary; among these, there are certainly coagulation disorders. In the history of medicine, autopsies and tissue sampling have played a fundamental role in order to understand the pathogenesis of emerging diseases, including infectious ones; compared to the past, histopathology can be now expanded by innovative techniques and modern technologies. For the first time in worldwide literature, we provide a detailed postmortem and biopsy report on the marked increase, up to 1 order of magnitude, of naked megakaryocyte nuclei in the bone marrow and lungs from serious COVID-19 patients. Most likely related to high interleukin-6 serum levels stimulating megakaryocytopoiesis, this phenomenon concurs to explain well the pulmonary abnormal immunothrombosis in these critically ill patients, all without molecular or electron microscopy signs of megakaryocyte infection.
Предметные рубрики MeSH
AdultAgedAutopsyBetacoronavirusBone MarrowCOVID-19Cell NucleusCoronavirus InfectionsCritical IllnessCytokine Release SyndromeDisseminated Intravascular CoagulationFatal OutcomeHost-Pathogen InteractionsHumansInterleukin-6LungMaleMegakaryocytesMiddle AgedPandemicsPneumonia, ViralSARS-CoV-2Severity of Illness IndexThrombopoiesisThrombosis